Description
Grasil injection is a brand form of amikacin (an aminoglycoside antibiotic). It is used to treat serious bacterial infections caused by organisms susceptible to amikacin. The 1 ml ampoule delivers 25 mg of amikacin. The injectable formulation ensures rapid and direct systemic availability. 
Ingredients
- 
Active ingredient: Amikacin sulfate equivalent to 25 mg per 1 ml ampoule 
 
- 
Excipients / inactives: Water for injection, stabilizers, buffers, etc. (as per manufacturer) 
 
Drug Class
Aminoglycoside antibiotic (bactericidal, concentration-dependent) 
Dosage Form
Sterile injectable solution — 1 ml ampoule containing 25 mg amikacin 
Uses (Indications)
Grasil (amikacin) is indicated for serious infections caused by Gram-negative bacteria or those resistant to other antibiotics, such as:
- 
Bacteremia / sepsis
 
- 
Lower respiratory tract infections
 
- 
Intra-abdominal infections
 
- 
Urinary tract infections
 
- 
Bone and joint infections
 
- 
Skin & soft tissue infections
 
- 
Postoperative infections
 
- 
Others where a potent aminoglycoside is needed 
 
Dosage
- 
The dose for amikacin is typically calculated based on patient weight and renal function. 
 
- 
A commonly used regimen is 15 mg/kg per day, divided into multiple doses or sometimes once daily, depending on severity and pharmacokinetics. 
 
- 
In your product case (25 mg per 1 ml ampoule), multiple ampoules might be used to reach the needed dose depending on weight, under medical guidance.
 
- 
Dose adjustments in renal impairment are critical. 
 
In Case of Overdose
- 
Potential symptoms: hearing damage (ototoxicity), kidney damage (nephrotoxicity), neuromuscular blockade (weakness), vestibular toxicity (dizziness) 
 
- 
Treatment: supportive care, stopping the drug, monitoring kidney function, hearing tests, hydration, monitoring of electrolytes.
 
Missed Dose
- 
In clinical settings, missing a dose must be evaluated by the treating physician.
 
- 
Do not double up the next dose to compensate.
 
How To Use / Administration
- 
Administer intravenous (IV) or intramuscular (IM) routes. 
 
- 
For IV, infusion over 30–60 minutes is common to reduce toxicity risk. 
 
- 
Use aseptic technique.
 
- 
Monitor patient during and after administration (renal function, hearing, balance, vital signs).
 
When Not to Use (Contraindications)
- 
Known hypersensitivity or allergic reaction to amikacin or aminoglycosides 
 
- 
Pre-existing hearing loss or vestibular dysfunction
 
- 
Severe renal impairment (unless dose adjustment)
 
- 
Myasthenia gravis or neuromuscular diseases (risk of neuromuscular blockade)
 
- 
Pregnancy and lactation: use only if benefits outweigh risks (aminoglycosides can cross placenta)
 
- 
Use with caution in the elderly
 
Side Effects
Common / less serious:
Serious / toxic:
- 
Ototoxicity (hearing loss, tinnitus, vestibular damage) 
 
- 
Nephrotoxicity (renal damage) 
 
- 
Neuromuscular blockade, especially in susceptible individuals
 
- 
Allergic reactions (rash, anaphylaxis)
 
Precautions & Warnings
- 
Regularly monitor renal function (serum creatinine, BUN) 
 
- 
Monitor auditory and vestibular function (hearing tests) 
 
- 
Hydration is important to reduce nephrotoxicity
 
- 
Avoid use with other nephrotoxic or ototoxic drugs
 
- 
Use the lowest effective dose for shortest duration
 
- 
Inform surgical / dental teams of amikacin use
 
Drug Interactions
- 
Concurrent use of other nephrotoxic agents (e.g., aminoglycosides, vancomycin, cisplatin, loop diuretics) increases kidney risk 
 
- 
Other ototoxic drugs (e.g., loop diuretics) may add hearing risk
 
- 
Neuromuscular blocking agents (e.g., suxamethonium, tubocurarine) may have additive effects on muscle weakness
 
Storage / Disposal
- 
Store at controlled room temperature, below recommended maximum (often ≤ 25–30 °C) 
 
- 
Protect from light, moisture
 
- 
Do not freeze
 
- 
Use before expiry
 
- 
Dispose unused/expired ampoules safely as medical waste
 
Control Drug Status
Quick Tips
- 
Always adjust dose for renal function
 
- 
Use slow infusion to minimize toxicity
 
- 
Monitor hearing and kidney parameters during therapy
 
- 
Avoid combining with other harmful drugs
 
- 
Use minimal effective duration
 
- 
Inform patients of signs of hearing loss or dizziness